Clark Wealth Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.9K Buy
489
+178
+57% +$4.73K 0.01% 223
2026
Q2
$7.48K Buy
311
+22
+8% +$575 ﹤0.01% 255
2026
Q1
$8.13K Sell
289
-536
-65% -$14.3K 0.01% 270
2025
Q4
$20.5K Hold
825
– – 0.01% 174
2025
Q3
$20.5K Sell
825
-13,232
-94% -$327K 0.01% 174
2025
Q2
$341K Sell
14,057
-11
-0.1% -$257 0.23% 41
2025
Q1
$356K Buy
14,068
+240
+2% +$6.28K 0.26% 38
2024
Q4
$367K Buy
+13,828
New +$375K 0.28% 39

Other funds holding PFE

Clark Wealth Partners's PFE Position: Q3 2026 in Review

Clark Wealth Partners increased its Pfizer (PFE) stake by 57% in Q3 2026, buying an estimated $4.73K and bringing the position to 489 shares worth $13.9K. The position accounts for 0.01% of the portfolio, ranked #223.

Clark Wealth Partners first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. The position peaked at $367K in Q4 2024. 2,920 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Clark Wealth Partners held 489 shares of Pfizer worth $13.9K as of Q3 2026.
  • Clark Wealth Partners bought 178 Pfizer shares in Q3 2026, an estimated $4.73K.
  • Pfizer made up 0.01% of Clark Wealth Partners's portfolio in Q3 2026, its #223 holding.
  • Clark Wealth Partners first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • Clark Wealth Partners's Pfizer position peaked at $367K in Q4 2024.
  • 2,920 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Clark Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.